Boston Common Asset Management LLC Has $285,000 Stake in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Boston Common Asset Management LLC lifted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 505.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 18,065 shares of the company’s stock after buying an additional 15,080 shares during the period. Boston Common Asset Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $285,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in shares of Dr. Reddy’s Laboratories by 12.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock worth $76,455,000 after buying an additional 114,294 shares during the period. State Street Corp grew its position in shares of Dr. Reddy’s Laboratories by 1.9% during the 3rd quarter. State Street Corp now owns 909,905 shares of the company’s stock worth $72,292,000 after buying an additional 16,641 shares during the period. Fisher Asset Management LLC grew its position in shares of Dr. Reddy’s Laboratories by 59.4% during the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock worth $39,034,000 after buying an additional 183,146 shares during the period. BNP Paribas Financial Markets grew its position in Dr. Reddy’s Laboratories by 30.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 409,440 shares of the company’s stock valued at $32,530,000 after purchasing an additional 96,339 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund grew its position in Dr. Reddy’s Laboratories by 318.0% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock valued at $28,411,000 after purchasing an additional 283,700 shares during the period. Institutional investors and hedge funds own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Price Performance

RDY opened at $14.91 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The company has a market capitalization of $12.44 billion, a price-to-earnings ratio of 23.82 and a beta of 0.51. The firm’s fifty day moving average price is $14.86 and its two-hundred day moving average price is $15.55. Dr. Reddy’s Laboratories Limited has a 1 year low of $13.47 and a 1 year high of $16.89.

Analysts Set New Price Targets

RDY has been the subject of several research reports. StockNews.com downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Barclays reduced their price target on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th. Finally, Nomura downgraded shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.